Stock Track | Maravai LifeSciences Plunges 18.70% Pre-Market as Q4 Earnings Postponed Due to Revenue Recognition Issues, Internal Control Weakness

Stock Track

Feb 25, 2025

Maravai LifeSciences Holdings, Inc. (MRVI) stock plummeted 18.70% in pre-market trading on Tuesday after the company announced it is postponing its Q4 2024 earnings release and conference call from February 25th to March 18th. MRVI also said it will delay filing its annual report for the year ended December 31, 2024.

The key reasons cited by Maravai for the delay are the need for more time to assess a potential non-cash impairment charge related to goodwill from its acquisition of Alphazyme LLC. Additionally, the company is reviewing an error where $3.9 million in revenue was incorrectly recorded in Q2 2024 instead of Q3 2024, though this is not expected to impact full-year 2024 revenue guidance.

Perhaps most concerning for investors is that Maravai requires additional time to complete its assessment of internal controls over financial reporting as of year-end 2024. The company has identified a material weakness specifically in its internal controls over revenue recognition, which likely contributed to the stock's sharp sell-off on Tuesday.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1108038227"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1108038227\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1108038227?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-25 22:49","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1108038227","market":"hk","top_or_hot":-1,"title":"Stock Track | Maravai LifeSciences Plunges 18.70% Pre-Market as Q4 Earnings Postponed Due to Revenue Recognition Issues, Internal Control Weakness","media":"Stock Track","content":"<p>Maravai LifeSciences Holdings, Inc. (MRVI) stock plummeted 18.70% in pre-market trading on Tuesday after the company announced it is postponing its Q4 2024 earnings release and conference call from February 25th to March 18th. MRVI also said it will delay filing its annual report for the year ended December 31, 2024.</p>\n\n<p>The key reasons cited by Maravai for the delay are the need for more time to assess a potential non-cash impairment charge related to goodwill from its acquisition of Alphazyme LLC. Additionally, the company is reviewing an error where $3.9 million in revenue was incorrectly recorded in Q2 2024 instead of Q3 2024, though this is not expected to impact full-year 2024 revenue guidance.</p>\n\n<p>Perhaps most concerning for investors is that Maravai requires additional time to complete its assessment of internal controls over financial reporting as of year-end 2024. The company has identified a material weakness specifically in its internal controls over revenue recognition, which likely contributed to the stock's sharp sell-off on Tuesday.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Maravai LifeSciences Plunges 18.70% Pre-Market as Q4 Earnings Postponed Due to Revenue Recognition Issues, Internal Control Weakness</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Maravai LifeSciences Plunges 18.70% Pre-Market as Q4 Earnings Postponed Due to Revenue Recognition Issues, Internal Control Weakness\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-02-25 22:49</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Maravai LifeSciences Holdings, Inc. (MRVI) stock plummeted 18.70% in pre-market trading on Tuesday after the company announced it is postponing its Q4 2024 earnings release and conference call from February 25th to March 18th. MRVI also said it will delay filing its annual report for the year ended December 31, 2024.</p>\n\n<p>The key reasons cited by Maravai for the delay are the need for more time to assess a potential non-cash impairment charge related to goodwill from its acquisition of Alphazyme LLC. Additionally, the company is reviewing an error where $3.9 million in revenue was incorrectly recorded in Q2 2024 instead of Q3 2024, though this is not expected to impact full-year 2024 revenue guidance.</p>\n\n<p>Perhaps most concerning for investors is that Maravai requires additional time to complete its assessment of internal controls over financial reporting as of year-end 2024. The company has identified a material weakness specifically in its internal controls over revenue recognition, which likely contributed to the stock's sharp sell-off on Tuesday.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MRVI","symbol_name":"Maravai LifeSciences Holdings, Inc.","start_time":0,"source_url":"","article_id":"1108038227","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1108038227","pubTimestamp":1740494977,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Maravai LifeSciences Holdings, Inc.  stock plummeted 18.70% in pre-market trading on Tuesday after the company announced it is postponing its Q4 2024 earnings release and conference call from February 25th to March 18th. MRVI also said it will delay filing its annual report for the year ended December 31, 2024.The key reasons cited by Maravai for the delay are the need for more time to assess a potential non-cash impairment charge related to goodwill from its acquisition of Alphazyme LLC. Additi","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MRVI":"Maravai LifeSciences Holdings, Inc."},"translate_title":"股票赛道Maravai LifeSciences盘前暴跌18.70%，因收入确认问题、内部控制薄弱导致Q4财报推迟","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MRVI":1},"content_text":"Maravai LifeSciences Holdings, Inc. (MRVI) stock plummeted 18.70% in pre-market trading on Tuesday after the company announced it is postponing its Q4 2024 earnings release and conference call from February 25th to March 18th. MRVI also said it will delay filing its annual report for the year ended December 31, 2024.\nThe key reasons cited by Maravai for the delay are the need for more time to assess a potential non-cash impairment charge related to goodwill from its acquisition of Alphazyme LLC. Additionally, the company is reviewing an error where $3.9 million in revenue was incorrectly recorded in Q2 2024 instead of Q3 2024, though this is not expected to impact full-year 2024 revenue guidance.\nPerhaps most concerning for investors is that Maravai requires additional time to complete its assessment of internal controls over financial reporting as of year-end 2024. The company has identified a material weakness specifically in its internal controls over revenue recognition, which likely contributed to the stock's sharp sell-off on Tuesday.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}